Function, structure and regulation of the vacuolar (H+)-ATPases.

Archives of Biochemistry and Biophysics
Kevin JefferiesM Forgac

Abstract

The vacuolar ATPases (or V-ATPases) are ATP-driven proton pumps that function to both acidify intracellular compartments and to transport protons across the plasma membrane. Intracellular V-ATPases function in such normal cellular processes as receptor-mediated endocytosis, intracellular membrane traffic, prohormone processing, protein degradation and neurotransmitter uptake, as well as in disease processes, including infection by influenza and other viruses and killing of cells by anthrax and diphtheria toxin. Plasma membrane V-ATPases are important in such physiological processes as urinary acidification, bone resorption and sperm maturation as well as in human diseases, including osteopetrosis, renal tubular acidosis and tumor metastasis. V-ATPases are large multi-subunit complexes composed of a peripheral domain (V(1)) responsible for hydrolysis of ATP and an integral domain (V(0)) that carries out proton transport. Proton transport is coupled to ATP hydrolysis by a rotary mechanism. V-ATPase activity is regulated in vivo using a number of mechanisms, including reversible dissociation of the V(1) and V(0) domains, changes in coupling efficiency of proton transport and ATP hydrolysis and changes in pump density through rever...Continue Reading

References

Jan 26, 1996·The Journal of Biological Chemistry·G F BrisseauO D Rotstein
Jan 26, 1996·The Journal of Biological Chemistry·Q LiuM Forgac
Mar 20, 1997·Nature·H NojiK Kinosita
May 2, 1997·The Journal of Biological Chemistry·Q LiuM Forgac
Feb 7, 1998·The Journal of Biological Chemistry·K J MacLeodM Forgac
Apr 18, 1998·The EMBO Journal·T AzumaD J Kwiatkowski
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·W GüntherT J Jentsch
Jul 25, 1998·The Journal of Biological Chemistry·Y Kato-YamadaM Yoshida
Feb 27, 1999·Current Opinion in Cell Biology·D J Kwiatkowski
Oct 3, 1999·The Journal of Biological Chemistry·T XuM Forgac
Jan 5, 2000·The Journal of Biological Chemistry·E VasilyevaM Forgac
Mar 14, 2000·The Journal of Biological Chemistry·F Gu, J Gruenberg
Apr 5, 2000·The Journal of Biological Chemistry·F B Schapiro, S Grinstein
Apr 27, 2000·The Journal of Biological Chemistry·K J ParraP M Kane
May 29, 2000·The Journal of Biological Chemistry·B PowellT H Stevens
Aug 1, 2000·The Journal of Biological Chemistry·L S HollidayS L Gluck
Dec 2, 2000·Nature Genetics·S Smith
Jun 21, 2001·Proceedings of the National Academy of Sciences of the United States of America·M SagermannB W Matthews
Sep 5, 2001·The Journal of Biological Chemistry·S Wilkens, M Forgac
Oct 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·S Kawasaki-NishiM Forgac
Feb 12, 2002·Nature Reviews. Molecular Cell Biology·Tsuyoshi Nishi, Michael Forgac
Feb 15, 2002·The Journal of Biological Chemistry·Anne M SmardonPatricia M Kane
Jul 23, 2002·The Journal of Biological Chemistry·Yoshiko MurataMasamitsu Futai
Dec 17, 2002·The Journal of Biological Chemistry·Tsuyoshi NishiMichael Forgac

❮ Previous
Next ❯

Citations

Jul 29, 2009·Analytical and Bioanalytical Chemistry·Claus Hélix Nielsen
Dec 17, 2008·Calcified Tissue International·Anna VillaCristina Sobacchi
Nov 20, 2012·European Biophysics Journal : EBJ·Csilla FerenczTibor Páli
Oct 1, 2011·Molecular Genetics and Genomics : MGG·Sandra C Dos Santos, Isabel Sá-Correia
Jul 30, 2009·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Elena AndreucciIvana Pela
Jul 30, 2010·Quarterly Reviews of Biophysics·Kutti R Vinothkumar, Richard Henderson
Feb 23, 2012·Nature Communications·Alastair G StewartDaniela Stock
Mar 29, 2013·Nature Communications·Mallika ValapalaDebasish Sinha
Dec 30, 2009·Prostate Cancer and Prostatic Diseases·L G SmythR W G Watson
Sep 15, 2010·The Journal of Biological Chemistry·Norbert KartnerMorris F Manolson
Sep 6, 2012·The Journal of Biological Chemistry·Kalyan C KondapalliRajini Rao
Aug 13, 2010·Molecular Biology of the Cell·Eric J R JansenGerard J M Martens
Apr 27, 2010·Eukaryotic Cell·César M Camilo, Suely L Gomes
Jan 21, 2011·Physiological Reviews·James A McCormick, David H Ellison
Jan 7, 2010·PloS One·Margaret ClarkeGünther Gerisch
Sep 15, 2010·PloS One·Zacariah L HildenbrandRicardo A Bernal
Aug 21, 2013·PloS One·Jianxiu YaoAnna E Whitfield
Jul 22, 2011·Genetics·Amy L AdamsonDennis LaJeunesse
Dec 1, 2009·Cellular and Molecular Life Sciences : CMLS·Eric J R JansenGerard J M Martens
Jul 10, 2012·Human Genetics·Björn FischerUwe Kornak
Jul 22, 2014·Cellular & Molecular Immunology·Kenneth D BeamanAlice Gilman-Sachs
May 25, 2011·The Journal of Cell Biology·Michael CarnellRobert H Insall
May 24, 2011·Expert Opinion on Drug Safety·Laura E Targownik, William D Leslie
May 19, 2011·Annals of Medicine·Antti RivinojaSakari Kellokumpu
Jul 8, 2015·Proceedings of the National Academy of Sciences of the United States of America·Daniel MontielSean F Brady
Dec 19, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·David A Johnson, Edward C Oldfield
Jun 2, 2012·The International Journal of Biochemistry & Cell Biology·A QinM H Zheng
Jan 17, 2012·Journal of Neuroimmunology·Takeshi FujiiKoichiro Kawashima
Dec 3, 2011·Journal of Insect Physiology·Otto Baumann, Bernd Walz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

© 2022 Meta ULC. All rights reserved